{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m nalidixic acid
to a specific field?
Status:
Possibly Marketed Outside US
Source:
BLA125296
(2011)
Source URL:
First approved in 1986
Source:
ANDA070994
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
First approved in 1984
Source:
NeuroBion by BENARD INDUSTRIES INC
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT02607319: Phase 4 Interventional Completed Sterility
(2015)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT02630095: Phase 4 Interventional Unknown status Portal Vein Thrombosis
(2015)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT00196417: Phase 4 Interventional Unknown status Heparin-Induced Thrombocytopenia
(2003)
Source URL:
Class:
POLYMER
Status:
US Approved OTC
Source:
21 CFR 349.12(a)(3) ophthalmic:demulcents hypromellose
Source URL:
First approved in 1974
Source:
NDA200890
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Investigational
Source:
NCT02155673: Phase 2 Interventional Completed Chronic Kidney Disease
(2014)
Source URL:
Class:
STRUCTURALLY DIVERSE
